ArticleArchives of microbiology2025
Antibacterial and antibiofilm efficacy of ar-turmerone derived from Curcuma longa L. arrested multidrug-resistant pathogenic Gram-positive bacteria.
Article in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fabrication of a Multifunctional CoFeACS omega · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The antibacterial and antibiofilm efficacy of ar-turmerone, a major constituent of Curcuma longa essential oil, against Gram-positive clinical pathogenic strains of bacteria was evaluated in this study. ar-turmerone was extracted from turmeric essential oil using silica gel column chromatography and characterized by nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS), and high-performance liquid chromatography (HPLC). Antibacterial efficacy was tested via broth microdilution to determine minimum inhibitory concentration (MIC) values against Staphylococcus aureus (ATCC and clinical isolate), S. epidermidis clinical isolate, Enterococcus faecalis clinical isolate, and Streptococcus viridans clinical isolate. Biofilm inhibition (minimum biofilm inhibitory concentration, MBIC) and eradication (minimum biofilm eradication concentration, MBEC) were assessed using crystal violet assays and bactericidal effect was then confirmed using resazurin viability assay and live/dead fluorescence microscopy. Ar-turmerone's activity was compared with its crude source, turmeric essential oil, to demonstrate the potency gained upon purification. Gentamicin and quercetin served as controls for antibacterial and antibiofilm effects, respectively. Scanning electron microscopy confirmed disruption of biofilm structure post-treatment. Ar-turmerone exhibited significantly lower MIC, MBIC and MBEC values than the turmeric essential oil and the standard drugs. Cytotoxicity testing on HEK 293 and L929 fibroblast cells showed that ar-turmerone was highly biocompatible (IC₅₀ = 11.09 mM in HEK 293; no cytotoxicity in L929 up to 9.25 mM). This study provides a comprehensive in vitro evaluation of ar-turmerone's antibacterial, biofilm inhibitory and eradication potential. The efficacy of ar-turmerone against biofilm-forming, drug-resistant Gram-positive pathogens and low cytotoxicity established the compound for future development as a plant-derived antimicrobial agent.
Indexed as
Identifiers
41249569What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.